Nathan John Robison, MD

Associate Professor of Clinical Pediatrics

Image of Nathan John Robison, MD
Is this your profile? Click to edit

Overview

After completing his residency and fellowship at Children’s Hospital Los Angeles, Dr. Robison completed an additional fellowship in Pediatric Neuro-Oncology at the Dana-Farber / Children’s Hospital Cancer Center in Boston. He served as clinical instructor at Harvard Medical School and attending staff in the Pediatric Neuro-Oncology Program at Dana Farber Cancer Institute and Boston Children’s Hospital from 2010 to 2013.

In April 2013 he joined the faculty of the University of Southern California Keck School of Medicine as assistant professor of pediatrics, and now serves as attending staff in the Pediatric Neuro-Oncology Program at Children’s Hospital Los Angeles.

Dr. Robison’s primary research focus is developing clinical trials that test new strategies in the treatment of children with brain tumors. Specific areas of interest include molecular targeted treatment of low-grade glioma, diffuse pontine glioma, and medulloblastoma; novel treatments targeting the tumor microenvironment, including antiangiogenic and immunomodulatory strategies; and neurofibromatosis.

Publications

  • Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG. Clin Cancer Res. 2026 Jun 30.. View in PubMed
  • Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncol Pract. 2026 Jun 22.. View in PubMed
  • Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma. Neuro Oncol. 2026 May 19.. View in PubMed
  • FOXR2-activated CNS neuroblastoma: Characterized by variable structural disruption of the FOXR2 regulatory region, recurrent copy number alterations, and elevated FOXR2 expression. Neurooncol Pediatr. 2026 Apr; 2(2):wuag014.. View in PubMed
  • Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs. Neurooncol Pract. 2026 Jun; 13(3):620-633.. View in PubMed
  • A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4. Neuro Oncol. 2025 Oct 14; 27(9):2415-2428.. View in PubMed
  • Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.. View in PubMed
  • ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. J Clin Oncol. 2025 02 20; 43(6):716-729.. View in PubMed
  • Lack of classical astroblastoma features in pediatric MN1::BEND2-fused brain tumors. Brain Pathol. 2025 Mar; 35(2):e13297.. View in PubMed
  • Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro Oncol. 2024 08 05; 26(8):1357-1366.. View in PubMed